Compare ARQT & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARQT | TWST |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 5.2B |
| IPO Year | 2020 | 2018 |
| Metric | ARQT | TWST |
|---|---|---|
| Price | $27.41 | $91.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $34.00 | ★ $46.88 |
| AVG Volume (30 Days) | 1.7M | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.79 | 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | $376,072,000.00 | ★ $376,572,000.00 |
| Revenue This Year | $34.85 | $18.91 |
| Revenue Next Year | $29.39 | $15.07 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 91.34 | 20.32 |
| 52 Week Low | $13.06 | $23.30 |
| 52 Week High | $31.77 | $89.71 |
| Indicator | ARQT | TWST |
|---|---|---|
| Relative Strength Index (RSI) | 73.65 | 75.02 |
| Support Level | $24.81 | $41.85 |
| Resistance Level | $28.80 | N/A |
| Average True Range (ATR) | 1.20 | 5.69 |
| MACD | 0.46 | 1.25 |
| Stochastic Oscillator | 88.31 | 91.38 |
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.